Question

Difficulty: MediumRheumatology and Immunology

An evaluation is requested for a 53-year-old woman who presents to the clinic reporting a three-week history of progressively worsening shortness of breath and new-onset lower extremity swelling. She reports waking up frequently during the night gasping for air. The patient has a 12-year history of seropositive rheumatoid arthritis that has been stable for the past two years on a regimen of methotrexate and infliximab. She also takes naproxen as needed for joint pain. Her temperature is 37.0°C (98.6°F), blood pressure is 138/85 mmHg, pulse is 96/min, and respiratory rate is 22/min. Pulse oximetry shows 94% on room air. Physical examination reveals jugular venous distention at 9 cm H2OH_2O. Lung auscultation demonstrates bibasilar fine crackles. Cardiac examination shows a regular rate and rhythm with a prominent S3 gallop. The abdomen is soft, and there is 2+ pitting edema of the lower extremities bilaterally. Joint examination shows ulnar deviation of the metacarpophalangeal joints but no acute synovitis or effusions. Laboratory studies reveal a hemoglobin of 11.2 g/dL, a normal comprehensive metabolic panel, a thyroid-stimulating hormone (TSH) level of 1.2 μ\mu U/mL (normal: 0.5-5.0 μ\mu U/mL), and a slightly decreased total T4T_4 level. Which of the following is the most appropriate next step in the management of this patient?

  1. Discontinue infliximab and obtain a transthoracic echocardiogramAnswer
  2. B
    Prescribe inhaled albuterol and a tapering dose of oral prednisone
  3. C
    Admit to the hospital for intravenous vancomycin and piperacillin-tazobactam
  4. D
    Administer the live-attenuated intranasal influenza vaccine
  5. E
    Initiate levothyroxine therapy for secondary hypothyroidism

Answer

The most appropriate next step is to discontinue infliximab and obtain a transthoracic echocardiogram.
The patient is presenting with classic signs of acute decompensated heart failure, including dyspnea, orthopnea, paroxysmal nocturnal dyspnea, bibasilar crackles, jugular venous distention, lower extremity edema, and an S3 gallop. A well-documented adverse effect of tumor necrosis factor-alpha (TNF-alpha) inhibitors (such as infliximab, adalimumab, and etanercept) is the initiation or exacerbation of heart failure. For a patient who develops new-onset heart failure while receiving a TNF-alpha inhibitor, the most critical next step is to immediately discontinue the offending agent. Following discontinuation, a transthoracic echocardiogram is essential to evaluate the structural integrity of the heart, determine the left ventricular ejection fraction, and guide further pharmacological management, such as the initiation of loop diuretics.

Step-by-Step Solution

1
Identify the primary clinical syndrome from the patient's presentation.
The patient has orthopnea, paroxysmal nocturnal dyspnea, bibasilar crackles, jugular venous distention, peripheral edema, and an S3 gallop, which universally point to acute decompensated heart failure.
Recognizing the constellation of signs differentiates heart failure from primary pulmonary or infectious etiologies.
2
Review the patient's medication list for potential triggers of the clinical syndrome.
The patient is taking infliximab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor.
TNF-alpha inhibitors are known to cause or exacerbate heart failure in susceptible individuals.
3
Determine the appropriate management protocol for medication-induced heart failure.
The offending agent (infliximab) must be discontinued, and an echocardiogram should be performed to assess left ventricular function.
Continuing the biologic therapy will worsen the cardiac decompensation, and an echocardiogram is the standard diagnostic test to quantify the degree of cardiac dysfunction.

Key Concept

Tumor necrosis factor-alpha (TNF-alpha) inhibitors (e.g., infliximab, etanercept, adalimumab) can precipitate or exacerbate heart failure, requiring immediate discontinuation of the drug and cardiac evaluation.
Rate this question